100% Cancer Remission Achieved in ALL Patients in Groundbreaking Study

100% Cancer Remission Achieved in ALL Patients in Groundbreaking Study

Dr. Andrea Cercek, one of the lead researchers, said:

“It’s absolutely incredible … We’ve certainly never seen this before.”

All 12 patients experienced complete rectal cancer remission after receiving… pic.twitter.com/qRpVh8xAfo

— The Vigilant Fox 🦊 (@VigilantFox) April 7, 2025

Dr. Andrea Cercek, one of the lead researchers, said: “It’s absolutely incredible … We’ve certainly never seen this before.” All 12 patients experienced complete rectal cancer remission after receiving dostarlimab, a monoclonal antibody. This particular monoclonal antibody achieved 100% cancer remission without chemotherapy, radiation, surgery, or the toxic side effects that come with such therapies. The authors wrote: “All 12 patients (100%; 95% confidence interval) had a clinical complete response, with no evidence of tumor on magnetic resonance imaging … and no cases of progression or recurrence had been reported during follow-up (range, 6 to 25 months after treatment). No adverse events of grade 3 or higher have been reported.” How does this monoclonal antibody actually work? Dr. Andrea Cercek explained that it essentially unlocks the body’s ability to heal itself.

They would have hailed it a massive victory had only a fraction “showed marked improvement”. 100% remission in all patients, even with a group that small, is absolutely unheard of. This is beyond huge. – Steven Douglas
The lack of adverse events and the sustained remission during follow-up are equally impressive. Dr. Cercek’s description of the antibody’s mechanism of action, which enables the body to heal itself, is a testament to the incredible potential of immunotherapy. – Sergei G
In that study, all 12 patients achieving complete remission is a stunning result—100% response rate is rare in cancer trials. Dostarlimab works by blocking the PD-1 protein on immune cells, essentially unleashing the immune system to attack the cancer. The fact that it sidestepped the need for chemo, radiation, or surgery, and their associated side effects, is a game-changer for those patients. Dostarlimab is a monoclonal antibody, a type of drug designed to target specific proteins in the body. It works by boosting your immune system’s ability to fight cancer, particularly in cases like the rectal cancer patients with mismatch repair-deficient (dMMR) tumors. Here’s how it pulls that off: Normally, your immune system uses T-cells—think of them as the body’s attack dogs—to spot and destroy abnormal cells, like cancer. But cancer’s sneaky. It can hijack a protein called PD-1 (Programmed Death-1) on T-cells. When PD-1 binds to another protein, PD-L1, which is often overexpressed on cancer cells, it sends a signal that basically says, “Nothing to see here, move along.” This shuts down the T-cell attack, letting the cancer hide in plain sight. Dostarlimab steps in as a checkpoint inhibitor. It’s engineered to latch onto PD-1 and block that interaction with PD-L1. By doing so, it takes the brakes off the immune system. The T-cells stay active, recognize the cancer cells as threats, and go to work destroying them. In dMMR tumors, this is especially effective because these cancers have a ton of mutations—hundreds or thousands more than typical tumors. That makes them stand out like a sore thumb to the immune system once the PD-1 shield is down, leading to the kind of dramatic responses seen in the study. – Morality X